Amprenavir approved.
D019380:Anti-HIV Agents / Q000008:administration & dosage; D002219:Carbamates; D018849:Controlled Clinical Trials as Topic; D017277:Drug Approval; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008297:Male; D013449:Sulfonamides / Q000008:administration & dosage*; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D013449:Sulfonamides; C095108:amprenavir